Spanish biopharmaceutical company aptaTargets has transferred ApTOLL, a first-in-class TLR4 antagonist for acute ischemic stroke, to Merck KGaA, Darmstadt, Germany in an October 2024 agreement.
aptaTargets is advancing ApTOLL, an innovative aptamer-based immune modulator that reduces brain damage in acute ischemic stroke by targeting TLR4 receptors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.